Discovery of N-(4-aryl-5-aryloxy-thiazol-2-yl)-amides as potent RORγt inverse agonists
Yonghui Wang(Weifang People's Hospital), Xichen Lin(GlaxoSmithKline (China)), Ling Zhou(GlaxoSmithKline (China)), Yingli Ma(GlaxoSmithKline (China)), Qianqian Wu(GlaxoSmithKline (China)), Ziqiang Cheng(Shandong Agricultural University), Qian Liu(Guangxi Medical University), Yi Li(Baylor College of Medicine), Wei Zhang(Capital Medical University), Lisa A. Orband‐Miller(GlaxoSmithKline (China)), Ting Yang(GlaxoSmithKline (China)), Liuqing Yang(GlaxoSmithKline (China)), Feng Ren(Henan Medical University), John D. Elliott(GlaxoSmithKline (China)), Stewart Leung(GlaxoSmithKline (China)), Zhijun Xiang(GlaxoSmithKline (China)), Sijie Lu(GlaxoSmithKline (China)), Jia‐Ning Xiang(GlaxoSmithKline (China)), Kathleen Zhang(GlaxoSmithKline (China))
Cited by 32
Related Papers
AAV Vector Integration Sites in Mouse Hepatocellular Carcinoma
|Science|2007|648
RNA-seq of 272 gliomas revealed a novel, recurrent <i>PTPRZ1-MET</i> fusion transcript in secondary glioblastomas
|Genome Research|2014|425
Epigenetic-Mediated Dysfunction of the Bone Morphogenetic Protein Pathway Inhibits Differentiation of Glioblastoma-Initiating Cells
|Cancer Cell|2008|421